Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Primer-Based RNA Sequencing Analyzes RNA Transcripts in as Few as 50 Cells

By BiotechDaily International staff writers
Posted on 05 Nov 2013
Bioengineers have devised a new way to analyze RNA transcripts from as few as samples of 50 to 100 cells. The new strategy could be used to develop cost-effective and rapid techniques for detecting cancer at early stages, as well as better tools for drug discovery, forensics, and developmental biology.

The bioinformatic protocols, which were published in April 2013 in the journal Nature Scientific Reports, are now being applied to a wide range of biologic and medical research questions from brain cancer, to liver function and stem cell biology. The approach, developed by the University of California (UC) San Diego (USA) bioengineers, is called designed primer-based RNA sequencing (DP-seq). It is a new tool for generating comprehensive images of RNA—the “transcriptome”—gathered from as little as 50 pg of RNA. Transcriptome analysis provides clues into what biologic mechanisms are happening at a specific time. RNA transcripts serve as a substitute for which genes are being expressed and at what levels.

“In the months since we published the DP-seq protocol, there has been tremendous interest from the scientific community,” said. Shankar Subramaniam a bioengineering professor at the UC San Diego Jacobs School of Engineering and the corresponding author of the study. “When you are not restricted to samples of thousands of cells, there are so many more system-wide gene expression questions you can ask, and answer,” said Prof. Subramaniam. The investigators are looking for answers for questions such as what transcription factors will determine cell fates, such as cancer versus normal, and what pathways are likely to be activated in a tissue upon treatment with a drug?

In spite of the small amounts of RNA inputs required, the DP-seq protocol conserves the comparative profusion of RNA transcripts, even for low and moderately expressed transcripts. Furthermore, DP-seq can be used to target amplification of specific, medium, or lower abundance RNA transcripts by reducing amplification of highly abundant RNA transcripts. With targeted amplification, researchers can gain clues into the low and moderate frequency RNA transcripts that can get lost in the amplification process in other protocols.

“One of the exciting things about our protocol is that it has the potential to perform targeted amplification of genes of interest and/or specific regions of the transcriptome which carry disease-causing mutations or SNPs [single nucleotide polymorphisms]. Selective amplification of these transcripts will allow massive multiplexing of the samples, opening the door to cost-effective diagnostics,” said Vipul Bhargava, a graduate student in the Subramaniam laboratory and the first author on the article in Nature Scientific Reports.

To demonstrate this selective amplification, the researchers designed primers that suppressed amplification of highly expressing ribosomal transcripts in embryonic stem cells of mice. This, along with high sensitivity and the large dynamic range offered by DP-seq, uncovered RNA transcripts that had previously only been detected in later stages of embryonic development known as germ layer segregation.

“The majority of the novel transcripts that we identified in our study were low expressed. The high sensitivity in quantification of those transcripts and the large dynamic range offered by our protocol—over five orders of magnitude in RNA concentration—allowed us to detect the expression of these transcripts,” said Prof. Bhargava.

The DP-seq protocol is one of several approaches developed over the last two years capable of generating transcriptomes from approximately 50 pg of RNA. The new protocols from UC San Diego, however, offer clear advantages, the researchers reported. For example, by using 44 heptamer primers for cDNA amplification, the DP-seq approach generates transcriptomes faster and more economically than approaches that rely on full-length cDNA amplification of extremely small RNA samples.

The researchers hope to develop their technology for routine diagnosis of pathologies as well as for discovery of mechanisms and targets for therapeutic interventions. A patent has been filed for this technology, which is available for licensing.

DP-seq is a next-generation sequencing-based approach to whole transcriptome analysis. At its base is one of the central dogmas of biology: DNA is transcribed to form RNA, which is then translated to generate proteins, which may be modified before the proteins carry out their prescribed tasks.

Analyzing which RNA transcripts are present, and at what levels--transcriptome analysis—provides an outlook of system-wide gene expression patterns and a state of the system. “If you want to address a particular disease, the days of just looking into one gene, one protein or one signaling pathway are over. You need to look at all levels of complexity, all the way from genomic DNA to RNA to proteins, as well as how different modifications happen at the RNA and protein levels,” said Prof. Bhargava.

Applications such as DP-seq, which provide quantitative data on gene expression levels system-wide, are part of a move toward “systems health” in which researchers build systems-level models that describe biologic events and clarify what causes disease. Once the genes are identified that are changing their expression patterns, these genes can be studied as to how they interact with each other and build networks. Through these network models, one can begin to understand how specific changes within one network can affect the overall system. Understanding how perturbations in a system cause disease can lead to developing new therapies.

The early research raised issues that led the researchers better determine from a systems-level perspective such as how data from the continually growing list of “omics” tools can be integrated to construct models of biochemical pathways and mechanisms that will help understand healthy physiology as well as disease.

UC San Diego researchers are now using these types of models, and other new developments made possible by systems biology, to treat diseases, discover new drugs, and determine how organisms work at the molecular level.

Related Links:

University of California, San Diego



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.